© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
October 17th 2019
Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.
September 6th 2019
Sarah M. Larson, MD, discusses potentially practice-changing studies for patients with transplant-eligible and -ineligible multiple myeloma.